Program Description & Educational Objectives
In this activity, experts in insulin-dependent diabetes discuss the optimal management of patients in long-term care settings.
Upon completion of this activity, participants will be able to:
- Demonstrate the ability to translate knowledge of hyperglycemia treatment, including the benefits and risks, evidence-based management strategies, and practice guidelines in the LTC setting
- Improve the ability of LTC practitioners to employ collaborative team care techniques and utilize all available resources to provide consistent clinical practices and improve diabetes care in the LTC population
- Demonstrate improved patient outcomes, representing a reduction/closure of diabetes healthcare performance gaps (A1C, glycemic control, SSI therapy) in the regionally defined care systems
Target Audience
This activity has been designed to meet the educational needs of US physicians, medical directors, physician assistants, consultant pharmacists, nurse practitioners, nurses, and other healthcare professionals who are active in the management of patients with insulin-dependent diabetes.
Requirements for Successful Completion
In order to receive credit, participants must view the activity and complete the post-test and evaluation form. There are no pre-requisites and there is no fee to participate in this activity or to receive CME/CNE/CPE credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.
Media: Internet
Release and Expiration Dates: February 18, 2010 - February 17, 2011
Time to Complete: 30 minutes
Faculty & Disclosure
Course Director and Moderator
Derek LeRoith, MD, PhD
Professor of Medicine, Endocrinology, Diabetes and Bone Disease
Mt. Sinai School of Medicine
New York, New York
Derek LeRoith, MD, PhD,
has a financial interest/relationship or affiliation in the form of:
Consultant for AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Company; Merck & Co., Inc.; Pfizer Inc; and Takeda Pharmaceuticals North America, Inc.
Speakers Bureau participant with AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Company; Merck & Co., Inc.; Pfizer Inc; and Takeda Pharmaceuticals North America, Inc.
Advisory Board for AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Company; Merck & Co., Inc.; and sanofi-aventis.
Interviewees
Lawrence Blonde, MD, FACP, FACE
Director, Ochsner Diabetes Clinical Research Unit
Department of Endocrinology, Diabetes and Metabolic Diseases
Ochsner Medical Center
New Orleans, Louisiana
Lawrence Blonde, MD, FACP, FACE,
has a financial interest/relationship or affiliation in the form of:
Grant/Research Support from Amylin Pharmaceuticals, Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Eli Lilly and Company; MannKind Corporation; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Novo Nordisk Inc.; Pfizer Inc; Roche Laboratories Inc.; and sanofi-aventis.
Honoraria from Amylin Pharmaceuticals, Inc.; AstraZeneca Pharmaceuticals LP; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; Daiichi Sankyo, Inc.; Eli Lilly and Company; GlaxoSmithKline; Halozyme Therapeutics; LifeScan, Inc.; MannKind Corporation; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Novo Nordisk Inc.; Pfizer Inc; Roche Laboratories Inc.; sanofi-aventis; and VeroScience LLC.
Other Financial or Material Support from spouse, who is a stock shareholder in Amylin Pharmaceuticals, Inc. and Pfizer Inc in an account that is not part of their community property.
Charles A. Cefalu, MD, MS
Professor of Internal Medicine
Director, Geriatric Medicine Program
Co-Director, Center on Aging
Louisiana State University
New Orleans, Louisiana
Charles A. Cefalu, MD, MS,
currently has no financial interests/relationships or affiliations in relation to this activity.
Content Director
Annette Wiggins
PVI, PeerView Institute for Medical Education, Inc.
Annette Wiggins
currently has no financial interests/relationships or affiliations in relation to this activity.
All additional planning committee members, PVI, PeerView Institute for Medical Education, Inc. staff, and Purdue University School of Pharmacy staff have no relationships to disclose.
Sponsorship, Credit & Support
Physicians
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Purdue University School of Pharmacy and PVI, PeerView Institute for Medical Education. Purdue University School of Pharmacy, an equal access/equal opportunity institution, is accredited by the ACCME to provide continuing medical education for physicians.
Purdue University School of Pharmacy designates this educational activity for a maximum of 0.5 AMA PRA Category 1 CreditTM. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Nurses
Purdue University Continuing Nursing Education is approved as a provider of continuing nursing education by the Indiana State Nurses Association. ISNA is accredited as an approver of continuing education in nursing by the Commission on Accreditation of the American Nurses Credentialing Center. Code #CNEP-09-21.
This program has been approved for 1.0 contact hour(s).
Pharmacists
Purdue University School of Pharmacy and Pharmaceutical Sciences is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This is a knowledge-based, continuing education activity of Purdue University, an equal access/equal opportunity institution. Universal Program Number (UPN): 0018-9999-09-236-H01-P, 0.5 contact hours (0.05 CEUs).
This activity is supported by an educational grant from 
